Recombinant Mouse Interferon alpha 13 protein (rFc Tag) (HPLC verified)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Mouse Interferon alpha 13 protein (rFc Tag) (HPLC verified) (Eg4647)

Species

Mouse

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg4647

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse Interferon alpha 13 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Mouse Interferon alpha 13 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90 %, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse Interferon alpha 13 protein Cys24-Glu189 (Accession# Q80SU4) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 230396
• Accession: Q80SU4
• PredictedSize: 45.3 kDa
• SDS-PAGE: 45-55 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Interferon alpha 13 is predicted to enable cytokine activity and type I interferon receptor binding activity and is predicted to be involved in several processes, including B cell activation; lymphocyte activation involved in immune response; and positive regulation of peptidyl-serine phosphorylation of STAT protein.

References:

1.Lande R, et al. (1999) Ann N Y Acad Sci. 1183: 89-103.
2.Colonna M, et al. (2004) Nat Immunol. 5: 1219-1226.
3.Poeck H, et al. (2004) Blood. 103: 3058-3064.
4.Ablasser A, et al. (2009) J Immunol. 182: 6824-6833.
5.Liu C, et al. (2008) J Clin Invest. 118: 1165-1175.